Search

Your search keyword '"Harnett, Adrian N"' showing total 13 results
Start Over Author "Harnett, Adrian N"
13 results on '"Harnett, Adrian N"'

1. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Author

Agarwal, Roshan, Algurafi, Hafiz, Allerton, Rozenn, Archer, Caroline, Armstrong, Anne, Bale, Catherine, Barraclough, Lisa, Barthakur, Urmila, Bedi, Carolyn, Benstead, Kim, Bloomfield, David, Bowen, Rebecca, Bradley, Chris, Brown, Jane, Butt, Mohammad, Churn, Mark, Cleator, Susan, Cliff, Joanne, Crellin, Perric, Daly, Margaret, De Silva-Minor, Shiroma, Dhadda, Amandeep, Din, Omar, Down, Sue, Earl, Helena, Eaton, David, Eichholz, Andrew, Epurescu, Daniel, Goh, Chee, Goodman, Andrew, Grieve, Robert, Hadaki, Maher, Harper-Wynne, Catherine, Harries, Mark, Hayward, Larry, Humphreys, Alison, Innes, Helen, Jafri, Mariam, Jegannathen, Apurna, Kelleher, Muireann, Kristeleit, Hartmut, Lee, Daniela, Lupton, Susan, MacGregor, Carol, Malik, Zafar, Mansi, Janine, Marshall, Jennifer, McAdam, Karen, McGolick, Trevor, Mehra, Rakesh, Miles, David, Mithal, Natasha, Moss, Charlotte, Moss, Aian, Mukesh, Mukesh, Neal, Anthony, Nelmes, Daniel, Neville-Webbe, Helen, Newby, Jacqueline, O'Reilly, Susan, Ostler, Peter, Persic, Mojca, Pettit, Laura, Raj, Sanjay, Raja, Fharat, Rea, Daniel, Reed, Catherine, Rigg, Anne, Roe, Helen, Shah, Nihal, Simmonds, Peter, Sims, Eliot, Smith, Sarah, Storey, Nicola, Taylor, Wendy, Thanvi, Narottam, Tipples, Karen, Vaidya, Jayant, Varughese, Mohini, Vinayan, Anup, Walji, Nawaz, Waters, Simon, Woodings, Pamela, Wright, Kathryn, Yahya, Sundus, Earl, Helena M, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Howe, Donna, Raynes, Kerry, Higgins, Helen B, Wilcox, Maggie, Plummer, Chris, Gounaris, Ioannis, Mahler–Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Abraham, Jean E, Caldas, Carlos, Hall, Peter S, McCabe, Christopher, Hulme, Claire, Wardley, Andrew M, Cameron, David A, and Dunn, Janet A

Published
2019
Full Text
View/download PDF

2. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

Author

Al Sarakbi, Wail, Barber, Sarah, Barnett, Gillian, Bliss, Peter, Dewar, John, Eaton, David, Ebbs, Stephen, Ellis, Ian, Evans, Philip, Harris, Emma, James, Hayley, Kirwan, Cliona, Kirk, Julie, Mayles, Helen, McIntyre, Anne, Mills, Judith, Poynter, Andrew, Provenzano, Elena, Rawlings, Christine, Sculpher, Mark, Sumo, Georges, Sydenham, Mark, Tutt, Andrew, Twyman, Nicola, Venables, Karen, Winship, Anna, Winstanley, John, Wishart, Gordon, Thompson, Alastair, Coles, Charlotte E, Griffin, Clare L, Kirby, Anna M, Titley, Jenny, Agrawal, Rajiv K, Alhasso, Abdulla, Bhattacharya, Indrani S, Brunt, Adrian M, Ciurlionis, Laura, Chan, Charlie, Donovan, Ellen M, Emson, Marie A, Harnett, Adrian N, Haviland, Joanne S, Hopwood, Penelope, Jefford, Monica L, Kaggwa, Ronald, Sawyer, Elinor J, Syndikus, Isabel, Tsang, Yat M, Wheatley, Duncan A, Wilcox, Maggie, Yarnold, John R, and Bliss, Judith M

Published
2017
Full Text
View/download PDF

4. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Author

Earl, Helena M, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Howe, Donna, Raynes, Kerry, Higgins, Helen B, Wilcox, Maggie, Plummer, Chris, Mansi, Janine, Gounaris, Ioannis, Mahler-Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Abraham, Jean E, Caldas, Carlos, Hall, Peter S, McCabe, Christopher, Hulme, Claire, Miles, David, Wardley, Andrew M, Cameron, David A, Dunn, Janet A, PERSEPHONE Steering Committee And Trial Investigators, Earl, Helena [0000-0003-1549-8094], Abraham, Jean [0000-0003-0688-4807], Caldas, Carlos [0000-0003-3547-1489], and Apollo - University of Cambridge Repository

Subjects
Adult, Aged, 80 and over, Receptor, ErbB-2, Injections, Subcutaneous, Breast Neoplasms, Middle Aged, Trastuzumab, Disease-Free Survival, Drug Administration Schedule, United Kingdom, Young Adult, Antineoplastic Agents, Immunological, Treatment Outcome, Chemotherapy, Adjuvant, Humans, Female, Prospective Studies, Infusions, Intravenous, Aged
Abstract

BACKGROUND: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant trastuzumab treatment is non-inferior to the standard 12-month treatment regarding disease-free survival. METHODS: This study is an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in the UK. We randomly assigned patients with HER2-positive early breast cancer, aged 18 years or older, and with a clear indication for chemotherapy, by a computerised minimisation process (1:1), to receive either 6-month or 12-month trastuzumab delivered every 3 weeks intravenously (loading dose of 8 mg/kg followed by maintenance doses of 6 mg/kg) or subcutaneously (600 mg), given in combination with chemotherapy (concurrently or sequentially). The primary endpoint was disease-free survival, analysed by intention to treat, with a non-inferiority margin of 3% for 4-year disease-free survival. Safety was analysed in all patients who received trastuzumab. This trial is registered with EudraCT (number 2006-007018-39), ISRCTN (number 52968807), and ClinicalTrials.gov (number NCT00712140). FINDINGS: Between Oct 4, 2007, and July 31, 2015, 2045 patients were assigned to 12-month trastuzumab treatment and 2044 to 6-month treatment (one patient was excluded because they were double randomised). Median follow-up was 5·4 years (IQR 3·6-6·7) for both treatment groups, during which a disease-free survival event occurred in 265 (13%) of 2043 patients in the 6-month group and 247 (12%) of 2045 patients in the 12-month group. 4-year disease-free survival was 89·4% (95% CI 87·9-90·7) in the 6-month group and 89·8% (88·3-91·1) in the 12-month group (hazard ratio 1·07 [90% CI 0·93-1·24], non-inferiority p=0·011), showing non-inferiority of the 6-month treatment. 6-month trastuzumab treatment resulted in fewer patients reporting severe adverse events (373 [19%] of 1939 patients vs 459 [24%] of 1894 patients, p=0·0002) or stopping early because of cardiotoxicity (61 [3%] of 1939 patients vs 146 [8%] of 1894 patients, p

Published
2019
Full Text
View/download PDF

7. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Author

Earl, Helena M, primary, Hiller, Louise, additional, Vallier, Anne-Laure, additional, Loi, Shrushma, additional, McAdam, Karen, additional, Hughes-Davies, Luke, additional, Harnett, Adrian N, additional, Ah-See, Mei-Lin, additional, Simcock, Richard, additional, Rea, Daniel, additional, Raj, Sanjay, additional, Woodings, Pamela, additional, Harries, Mark, additional, Howe, Donna, additional, Raynes, Kerry, additional, Higgins, Helen B, additional, Wilcox, Maggie, additional, Plummer, Chris, additional, Mansi, Janine, additional, Gounaris, Ioannis, additional, Mahler–Araujo, Betania, additional, Provenzano, Elena, additional, Chhabra, Anita, additional, Abraham, Jean E, additional, Caldas, Carlos, additional, Hall, Peter S, additional, McCabe, Christopher, additional, Hulme, Claire, additional, Miles, David, additional, Wardley, Andrew M, additional, Cameron, David A, additional, Dunn, Janet A, additional, Agarwal, Roshan, additional, Algurafi, Hafiz, additional, Allerton, Rozenn, additional, Archer, Caroline, additional, Armstrong, Anne, additional, Bale, Catherine, additional, Barraclough, Lisa, additional, Barthakur, Urmila, additional, Bedi, Carolyn, additional, Benstead, Kim, additional, Bloomfield, David, additional, Bowen, Rebecca, additional, Bradley, Chris, additional, Brown, Jane, additional, Butt, Mohammad, additional, Churn, Mark, additional, Cleator, Susan, additional, Cliff, Joanne, additional, Crellin, Perric, additional, Daly, Margaret, additional, De Silva-Minor, Shiroma, additional, Dhadda, Amandeep, additional, Din, Omar, additional, Down, Sue, additional, Earl, Helena, additional, Eaton, David, additional, Eichholz, Andrew, additional, Epurescu, Daniel, additional, Goh, Chee, additional, Goodman, Andrew, additional, Grieve, Robert, additional, Hadaki, Maher, additional, Harper-Wynne, Catherine, additional, Hayward, Larry, additional, Humphreys, Alison, additional, Innes, Helen, additional, Jafri, Mariam, additional, Jegannathen, Apurna, additional, Kelleher, Muireann, additional, Kristeleit, Hartmut, additional, Lee, Daniela, additional, Lupton, Susan, additional, MacGregor, Carol, additional, Malik, Zafar, additional, Marshall, Jennifer, additional, McGolick, Trevor, additional, Mehra, Rakesh, additional, Mithal, Natasha, additional, Moss, Charlotte, additional, Moss, Aian, additional, Mukesh, Mukesh, additional, Neal, Anthony, additional, Nelmes, Daniel, additional, Neville-Webbe, Helen, additional, Newby, Jacqueline, additional, O'Reilly, Susan, additional, Ostler, Peter, additional, Persic, Mojca, additional, Pettit, Laura, additional, Raja, Fharat, additional, Reed, Catherine, additional, Rigg, Anne, additional, Roe, Helen, additional, Shah, Nihal, additional, Simmonds, Peter, additional, Sims, Eliot, additional, Smith, Sarah, additional, Storey, Nicola, additional, Taylor, Wendy, additional, Thanvi, Narottam, additional, Tipples, Karen, additional, Vaidya, Jayant, additional, Varughese, Mohini, additional, Vinayan, Anup, additional, Walji, Nawaz, additional, Waters, Simon, additional, Wright, Kathryn, additional, and Yahya, Sundus, additional

Published
2019
Full Text
View/download PDF

9. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

Author

Coles, Charlotte E, primary, Griffin, Clare L, additional, Kirby, Anna M, additional, Titley, Jenny, additional, Agrawal, Rajiv K, additional, Alhasso, Abdulla, additional, Bhattacharya, Indrani S, additional, Brunt, Adrian M, additional, Ciurlionis, Laura, additional, Chan, Charlie, additional, Donovan, Ellen M, additional, Emson, Marie A, additional, Harnett, Adrian N, additional, Haviland, Joanne S, additional, Hopwood, Penelope, additional, Jefford, Monica L, additional, Kaggwa, Ronald, additional, Sawyer, Elinor J, additional, Syndikus, Isabel, additional, Tsang, Yat M, additional, Wheatley, Duncan A, additional, Wilcox, Maggie, additional, Yarnold, John R, additional, Bliss, Judith M, additional, Al Sarakbi, Wail, additional, Barber, Sarah, additional, Barnett, Gillian, additional, Bliss, Peter, additional, Dewar, John, additional, Eaton, David, additional, Ebbs, Stephen, additional, Ellis, Ian, additional, Evans, Philip, additional, Harris, Emma, additional, James, Hayley, additional, Kirwan, Cliona, additional, Kirk, Julie, additional, Mayles, Helen, additional, McIntyre, Anne, additional, Mills, Judith, additional, Poynter, Andrew, additional, Provenzano, Elena, additional, Rawlings, Christine, additional, Sculpher, Mark, additional, Sumo, Georges, additional, Sydenham, Mark, additional, Tutt, Andrew, additional, Twyman, Nicola, additional, Venables, Karen, additional, Winship, Anna, additional, Winstanley, John, additional, Wishart, Gordon, additional, and Thompson, Alastair, additional

Published
2017
Full Text
View/download PDF

10. Angiosarcoma of the Scalp Presenting in Association With Borderline Malignant Phyllodes Tumour of the Breast

Author

Harden, Susan V., Ball, Richard Y., and Harnett, Adrian N.

Subjects
Article Subject
Abstract

Phyllodes tumours and angiosarcoma are both rare mesenchymal tumours. There are no reports of their coexistence in the literature except in families with germline p53 mutations. Here we report a case of an elderly woman who developed an extensive angiosarcoma of the scalp nearly 4 years after surgical removal of a borderline malignant phyllodes tumour of the breast. The scalp lesion was initially thought more likely to be a metastasis of her first rare tumour than a second equally rare primary tumour, but histologically this was not the case. The case and the literature are discussed.

Published
2003
Full Text
View/download PDF

11. Case Report.

Author

Harden, Susan V., Ball, Richard Y., and Harnett, Adrian N.

Subjects
ANGIOSARCOMA, DISEASES, SCALP, BREAST tumors, CANCER, DISEASES in older women, GERIATRIC gynecology
Abstract

Phyllodes tumours and angiosarcoma are both rare mesenchymal tumours. There are no reports of their coexistence in the literature except in families with germline p53 mutations. Here we report a case of an elderly woman who developed an extensive angiosarcoma of the scalp nearly 4 years after surgical removal of a borderline malignant phyllodes tumour of the breast. The scalp lesion was initially thought more likely to be a metastasis of her first rare tumour than a second equally rare primary tumour, but histologically this was not the case. The case and the literature are discussed. [ABSTRACT FROM AUTHOR]

Published
2003

12. Letters.

Author

Plummer, William P, Brugha, Traolach S, Fahey, Tom, Sullivan, Frank, MacGillivray, Steve, Henkel, Verena, Mergl, Roland, Hegerl, Ulrich, Kunkler, Ian H, Harnett, Adrian N, Sachs, Magda, Bronner, Andree, Phelps, Kerryn, Altman, Douglas G, Bydder, Sean, Bamji, Andrew N, Lee, W R, Richardson, Robert, and Simpson, David

Subjects
LETTERS to the editor, MEDICAL care, PRIMARY care, DIAGNOSIS of mental depression, RADIOTHERAPY complications, CARDIOVASCULAR emergencies, MORTALITY, BREAST cancer treatment, INFANT formulas, INFANT nutrition
Abstract

Presents letters to the editor in relation to medicine. Responses about screening for depression in primary care; Comments about cardiovascular mortality after radiotherapy for breast cancer; Views on the idea of monitoring the marketing of infant formula feeds.

Published
2003

13. The development and audit of a nurse-led urology/oncology clinic.

Author

McGlynn B, Meddings RN, al-Saffar N, Gurun M, Hollins GW, and Harnett AN

Subjects
Ambulatory Care Facilities, Humans, Medical Oncology, Nurse's Role, Patient Satisfaction, Program Development, Urology, Nursing Audit, Specialties, Nursing, Urologic Neoplasms nursing
Abstract

People with cancer in the UK should have access to a full spectrum of services. The role of the clinical nurse specialist is an important part of this development. In the specialty of urology/oncology, this role is still a relatively new development although the incidence of urological malignancy readily compares with other site-specific cancers.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results